Stockscreener 앱 받기
3.5857
2.12%
0.0557
전일 마감가:
$3.53
열려 있는:
$3.58
하루 거래량:
3.11M
Relative Volume:
0.82
시가총액:
$718.21M
수익:
$314.00K
순이익/손실:
$-40.23M
주가수익비율:
-12.81
EPS:
-0.28
순현금흐름:
$-84.71M
1주 성능:
+33.52%
1개월 성능:
+78.47%
6개월 성능:
+138.74%
1년 성능:
+129.62%
1일 변동 폭
$3.32
$3.62
1주일 범위
$2.67
$3.62
52주 변동 폭
$1.03
$3.62
Atai Life Sciences N V Stock (ATAI) Company Profile
명칭
Atai Life Sciences N V
전화
49 89 2153 9035
주소
WALLSTRASSE 16, BERLIN
ATAI을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ATAI
Atai Life Sciences N V
|
3.585 | 562.18M | 314.00K | -40.23M | -84.71M | -0.28 |
|
VRTX
Vertex Pharmaceuticals Inc
|
475.91 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.20 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.99 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
573.25 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
296.03 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Atai Life Sciences N V Stock (ATAI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-18 | 재확인 | H.C. Wainwright | Buy |
| 2024-04-03 | 업그레이드 | Maxim Group | Hold → Buy |
| 2022-11-01 | 개시 | Loop Capital | Buy |
| 2021-11-30 | 개시 | Maxim Group | Buy |
| 2021-11-11 | 개시 | ROTH Capital | Buy |
| 2021-10-18 | 개시 | H.C. Wainwright | Buy |
| 2021-09-01 | 개시 | Jefferies | Buy |
| 2021-07-13 | 개시 | Berenberg | Buy |
| 2021-07-13 | 개시 | Canaccord Genuity | Buy |
| 2021-07-13 | 개시 | Cantor Fitzgerald | Buy |
| 2021-07-13 | 개시 | Citigroup | Buy |
| 2021-07-13 | 개시 | Cowen | Outperform |
| 2021-07-13 | 개시 | Credit Suisse | Outperform |
| 2021-07-13 | 개시 | RBC Capital Mkts | Sector Perform |
| 2021-07-08 | 개시 | Aegis Capital | Buy |
모두보기
Atai Life Sciences N V 주식(ATAI)의 최신 뉴스
What analysts say about Atai Life Sciences N.V. stockFree Trading Strategy Suggestions - Autocar Professional
What drives Atai Life Sciences N.V. stock priceExponential return rates - jammulinksnews.com
Is Atai Life Sciences N.V. a good long term investmentHigh-octane financial growth - jammulinksnews.com
5-HT2 Agonist Clinical Trials 2025: EMA, PDMA, FDA Approvals, Medication, Therapies, Treatment Market, Mechanism of Action, Route of Administration, and Companies by DelveInsight - The Globe and Mail
atai Life Sciences (ATAI) Upgraded to Strong Buy: Here's Why - Yahoo Finance
atai Life Sciences Bets Big On Psychedelics For Mental Health - Finimize
ATAI Impresses, CDTX Navigates With Confidence, MTSR Builds Momentum, COGT Keeps Scaling The Summit… - RTTNews
Atai Life Sciences N.V. Stock Analysis and ForecastFastest return on investment - jammulinksnews.com
Don't Trip. These Psychedelic Stocks May Have Some Life in Them Yet - US News Money
Why Atai Life Sciences N.V. stock attracts strong analyst attentionBreakout Momentum Stocks - beatles.ru
why atai life sciences n.v. stock attracts strong analyst attentionDaily Breakout Picks - Newser
How Atai Life Sciences N.V. stock performs during market volatilityMomentum Swing Watchlist - Newser
Canaccord Genuity Lifts Atai Life Sciences N.V. (ATAI)’s Price Target To $12, Maintains Buy Rating - MSN
Aegis Capital Reaffirms Buy on Atai Life Sciences N.V. (ATAI) with $8 Target - Insider Monkey
Is atai Life Sciences (ATAI) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Atai Life Sciences, Beckley Psytech Announce Positive Topline Results for BPL-003 - Yahoo.co
13 Best German Stocks to Invest in Now - Insider Monkey
Retail investors are Atai Life Sciences N.V.'s (NASDAQ:ATAI) biggest owners and were rewarded after market cap rose by US$121m last week - Yahoo Finance
atai Life Sciences stock rating reiterated at Buy by Aegis Capital - Investing.com Australia
atai Life Sciences stock maintains Buy rating after positive Phase 2b results - Investing.com
atai Life Sciences stock price target raised to $12 by Canaccord on positive trial data - Investing.com Canada
Biotech Rips On Dual Announcement - The Globe and Mail
Atai Life Sciences’ Merger Sparks Market Buzz - timothysykes.com
Atai Life Sciences To Raise $50 Mln Via Private Placement To Fund Clinical Programs; Stock Up - Nasdaq
atai Life Sciences and Beckley Psytech Announce Positive Topline Results from the Phase 2b Study of BPL-003 in Patients with Treatment-Resistant Depression - GlobeNewswire
Cathie Wood’s ARK ETF adjusts portfolio, buys Tesla and ATAI stock - Investing.com
Atai Life Sciences N.V. announced that it expects to receive $50 million in funding - MarketScreener
Are Medical Stocks Lagging atai Life Sciences (ATAI) This Year? - Yahoo Finance
Compass’s Psychedelic Drug to Treat Depression Meets Goal in Trial - Bloomberg.com
Psychedelic advocates hopeful Trump administration will support space, STAT says - Yahoo Finance
ATAI Sees Potential Boost from U.S. Policy Shift on Psychedelics - GuruFocus
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LNSR, ATAI, ICAD on Behalf of Shareholders - GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LNSR, ATAI, ICAD on Behalf of Shareholders - GlobeNewswire Inc.
Atai Life Sciences N V (ATAI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.15%
0.50%
자본화:
|
볼륨(24시간):